<?xml version="1.0" encoding="utf-8"?>
<!-- Generator: Adobe Illustrator 26.3.1, SVG Export Plug-In . SVG Version: 6.00 Build 0)  -->
<svg version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px"
	 viewBox="0 0 1867 1389" style="enable-background:new 0 0 1867 1389;" xml:space="preserve">
<style type="text/css">
	.st0{fill:#4D4D4F;}
	.st1{font-family:'TradeGothicLTStd';}
	.st2{font-size:23px;}
	.st3{fill:#007A33;}
	.st4{font-family:'TradeGothicLTStd-Bold';}
	.st5{font-size:52px;}
	.st6{font-size:30.332px;}
	.st7{font-family:'TradeGothicLTStd-Bd2';}
	.st8{font-size:31px;}
	.st9{font-size:18.082px;}
	.st10{opacity:0.831;}
	.st11{fill:#FFFFFF;}
	.st12{fill:none;stroke:#BBBCBC;}
	.st13{fill:none;stroke:#FFFFFF;}
	.st14{font-size:38px;}
	.st15{font-size:25px;}
</style>
<text transform="matrix(1 0 0 1 0 1349)" class="st0 st1 st2">1. EVRENZO EU SmPC, September 2022.</text>
<text transform="matrix(1 0 0 1 0 1383)" class="st0 st1 st2">2. Barratt J et al. Adv Ther. 2021;38(10):5345–5360.</text>
<text transform="matrix(1 0 0 1 0 1258)" class="st0 st1 st2">ACM, all-cause mortality; CI, confidence interval; ESA, erythropoiesis-stimulating agent; HR, hazard ratio; MACE, Major Adverse Cardiovascular Event</text>
<text transform="matrix(1 0 0 1 0 117)" class="st3 st4 st5">Cardiovascular safety profile of EVRENZO vs.</text>
<text transform="matrix(1 0 0 1 0 171)" class="st3 st4 st5">ESA in patients on dialysis</text>
<text transform="matrix(1 0 0 1 569.1888 153.6684)" class="st3 st4 st6">1,2</text>
<text transform="matrix(1 0 0 1 0 965)" class="st0 st7 st8">It is recommended that patients on dialysis who are stable on ESA should not be switched unless there is a valid clinical reason</text>
<text transform="matrix(1 0 0 1 1728.823 954.6677)" class="st0 st7 st9">1</text>
<g transform="translate(-139 -277.726)">
	<path class="st3" d="M139,579h1553.3v92.5H139V579z"/>
	<g class="st10">
		<path class="st11" d="M139,945h1553.3V1156H139V945z"/>
		<path class="st12" d="M139.5,945.5h1552.3v210.1H139.5V945.5z"/>
	</g>
	<g class="st10">
		<path class="st11" d="M139,854.4h1553.3v92.5H139V854.4z"/>
		<path class="st12" d="M139.5,854.9h1552.3v91.5H139.5V854.9z"/>
	</g>
	<g class="st10">
		<path class="st11" d="M139,763.1h1553.3v92.5H139V763.1z"/>
		<path class="st12" d="M139.5,763.6h1552.3v91.5H139.5V763.6z"/>
	</g>
	<path class="st13" d="M337.4,579.4v90.4"/>
	<text transform="matrix(1 0 0 1 359.453 988.011)" class="st0 st1 st8">Numerically lower risk compared with ESA,</text>
	<text transform="matrix(1 0 0 1 359.453 1025.011)" class="st0 st1 st8">favourable trend towards EVRENZO</text>
	<text transform="matrix(1 0 0 1 837.3442 1014.6787)" class="st0 st1 st9">2</text>
	<text transform="matrix(1 0 0 1 360.453 621.422)" class="st11 st7 st14">Patients new to dialysis</text>
	<text transform="matrix(1 0 0 1 360.453 653.422)" class="st11 st7 st14">(≤4 months)</text>
	<text transform="matrix(1 0 0 1 1039.681 621.422)" class="st11 st7 st14">Patients stable on dialysis</text>
	<text transform="matrix(1 0 0 1 1039.681 653.422)" class="st11 st7 st14">(&gt;4 months) and stable on ESA</text>
	<path class="st13" d="M998.2,579.4v90.4"/>
	<g class="st10">
		<path class="st11" d="M139,671.5h1553.3v92.5H139V671.5z"/>
		<path class="st12" d="M139.5,672h1552.3v91.5H139.5V672z"/>
	</g>
	<g>
		<text transform="matrix(1 0 0 1 156.787 728.751)" class="st0 st1 st8">MACE</text>
		<text transform="matrix(1 0 0 1 156.787 821.267)" class="st0 st1 st8">MACE+</text>
		<text transform="matrix(1 0 0 1 361.165 728.751)" class="st0 st1 st8">HR 0.83 (95% CI 0.61–1.13)</text>
		<text transform="matrix(1 0 0 1 361.165 821.267)" class="st0 st1 st8">HR 0.76 (95% CI 0.57–1.00)</text>
		<text transform="matrix(1 0 0 1 1037.684 728.751)" class="st0 st1 st8">HR 1.18 (95% CI 1.00–1.38)</text>
		<text transform="matrix(1 0 0 1 1037.684 821.267)" class="st0 st1 st8">HR 1.03 (95% CI 0.90–1.19)</text>
	</g>
	<path class="st12" d="M336.8,671.5v484.8"/>
	<text transform="matrix(1 0 0 1 156.787 910.78)" class="st0 st1 st8">ACM</text>
	<path class="st12" d="M998.2,671.5v484.8"/>
	<text transform="matrix(1 0 0 1 357.872 909.78)" class="st0 st1 st8">HR 0.83 (95% CI 0.57–1.19)</text>
	<text transform="matrix(1 0 0 1 1037.684 910.78)" class="st0 st1 st8">HR 1.23 (95% CI 1.02–1.49)</text>
	<text transform="matrix(1 0 0 1 1037.684 988.011)" class="st0 st1 st8">Comparison of treatment effects</text>
	<text transform="matrix(1 0 0 1 1037.684 1025.011)" class="st0 st1 st8">cannot be reliably established</text>
	<text transform="matrix(1 0 0 1 1037.684 1062.011)" class="st0 st1 st8">due to the inherent risks of</text>
	<text transform="matrix(1 0 0 1 1037.684 1099.011)" class="st0 st1 st8">switching patients from</text>
	<text transform="matrix(1 0 0 1 1037.684 1136.011)" class="st0 st1 st8">ESA to EVRENZO</text>
	<text transform="matrix(1 0 0 1 1275.3271 1125.6786)" class="st0 st1 st9">1</text>
</g>
<g>
	<text transform="matrix(1 0 0 1 1577.75 95)" class="st0 st7 st15">EVRENZO (roxadustat)</text>
	<text transform="matrix(1 0 0 1 1539.2 125)" class="st0 st7 st15">IS NOT APPROVED FOR USE</text>
	<text transform="matrix(1 0 0 1 1564.55 155)" class="st0 st7 st15">IN THE UNITED STATES</text>
	<text transform="matrix(1 0 0 1 1547.175 19)" class="st0 st7 st15">This information is intended</text>
	<text transform="matrix(1 0 0 1 1551.35 49)" class="st0 st7 st15">for international audiences.</text>
</g>
</svg>
